Clinical Trial Shows Promise for Non-small Cell Lung Cancer

CHAPEL HILL, N.C. - A clinical trial led by UNC Lineberger physician-researcher Mark Socinski, MD has shown that Abraxane® -- a chemotherapy agent previously used for metastatic breast cancer – is effective as a first-line treatment for patients with advanced non-small cell lung cancer.

The Phase 3 trial, which was conducted at UNC and 101 other sites globally, enrolled more than 1000 patients in the study – one of the largest clinical studies ever conducted for non-small cell lung    cancer.

"This is exciting news for lung cancer patients and has important implications not only in late stage cancer but also in earlier stages of the disease," Socinski said.

Read full news release on Abraxis BioScience websiteIcon indicating that a link will open an external site..